Pluvicto (lutetium vipivotide tetraxetan)

pCPA File Number: 22315

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

Sponsor/Manufacturer:

Advanced Accelerator Applications

CADTH Project Number:

PC0297

pCPA Engagement Letter Issued:

2023-08-29

Negotiation Process Concluded:

Not Applicable